Baxter's Low Glucose PD Solutions Favorably Impacted Metabolic Measures ... - PharmiWeb.com (press release) PDF Print
PharmiWeb.com (press release)
Baxter International Inc. (NYSE: BAX) today announced results from two large, international multicenter trials demonstrating that a low glucose peritoneal dialysis (PD) regimen favorably impacted metabolic measures important for end-stage renal disease ...
BAXTER INTERNATIONAL INC. : Baxter's Low Glucose PD Solutions Favorably

...

 
Share |
Copyright © 2024 Global Dialysis. All Rights Reserved.